If you’ve turned on a television lately, chances are you heard a catchy jingle. One GLP-1 medication’s now-famous chorus, “Oh, oh, oh, Ozempic,” illustrates how direct-to-consumer drug ads have become part of our cultural wallpaper. But while these jingles are catchy, they are now under the federal microscope. 

In its latest 2027 budget request, the Food and Drug Administration asked Congress to authorize a crackdown on drug advertisements that it deems “misleading and confusing to consumers and patients.” This isn’t a new initiative — the FDA has already issued hundreds of warnings to drug manufacturers as part of an enforcement push.